Mexico In-vitro Diagnostics Market Report and Forecast 2025-2034

Market Likely to be Driven by Advancements in Technology and Demand for Quality Medical Care

In-vitro diagnostic devices (IVDs) are considered medical devices in Mexico; COFEPRIS does not differentiate the regulation between medical devices and in-vitro diagnostic devices. In-vitro diagnostic devices (IVDs) generally comprise reactants, controls, calibrators and equipment or devices with the help of which diagnosis is carried out. It is noteworthy that IVDs could be part of a medical diagnosis equipment and sold with it, but in terms of regulatory treatment, these are considered independent medical devices. For example, a glucometer device is considered medical equipment while the test strips are considered IVDs.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

In-vitro diagnostic products are classified as Class I or II, according to diagnosed parameters. In general, the Classification and Grouping Rules lay down that IVDs related to highly infectious or life-threatening illnesses must be considered class II medical devices; the rest are considered class I.

In developing countries, rising levels of income and standards of living are expected to stimulate a new, health-conscious populace seeking quality medical care, and drive the Mexico in-vitro diagnostics market. Key drivers are expected to be growing population, government insurance, patients that are newly insured, and modernized healthcare facilities.

Improved Ease of Use and Greater Reliability Likely to Boost Market Growth

In-vitro diagnostics (IVDs) are assays employed to conduct tests on clinical samples taken from the body, including blood, urine, or tissue. The assays seek to screen for disease, identify a medical condition, observe therapy usage, or prevent disease. Nearly seventy percent of medical decisions are made on the basis of data offered by in-vitro diagnostics (IVDs), thus, these have assumed critical importance in patient care. In recent years, IVDs have gained even more popularity due to their capability of saving lives through early identification of medical conditions. The use of IVDs to determine underlying genetic conditions in addition to diagnostic screening could prevent unnecessary suffering by a patient and decrease the scale of treatment required.

Improved ease-of-use and greater reliability has led to use of IVDs in home settings also. For example, users today easily perform tests to monitor blood glucose levels, determine urinary tract infections, monitor ovulation, and confirm pregnancy. Such tests enable individuals to manage their health and offer quick results to enable further medical action. These advantages are expected to drive the Mexico in-vitro diagnostics market.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Mexico In-vitro Diagnostics Market Segmentation

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Key Industry Players in the Market

The report presents a detailed analysis of the following key players in the Mexico in-vitro diagnostics market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• F Hoffmann-La Roche Ltd.
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Siemens Healthineer AG
• Abbott Laboratories
• Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.